JPRN-UMIN000004792
Recruiting
Phase 2
Phase II study of pre-emptive therapy for low-level positive cytomegalovirus antigenemia by low-dose valganciclovir after allogeneic hematopoietic stem cell transplantation - Pre-emptive therapy for low-level positive cytomegalovirus antigenemia by low-dose valganciclovir after allogeneic hematopoietic stem cell transplantation
Dept of Hematology/Oncology, Kyushu University Hospital, Fukuoka, Japan0 sites20 target enrollmentJanuary 1, 2011
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Patients with low-level positive cytomegalovirus antigenemia after allogeneic hematopoietic stem cell transplantation
- Sponsor
- Dept of Hematology/Oncology, Kyushu University Hospital, Fukuoka, Japan
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Negative cytomegalovirus antibodies of both of donors and recipients T\-cell depleted or CD34\-positive cell selected transplantation Gut GVHD (\>\=stage 2\) HLA more than 2 locus disparity
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Phase I/II study of Second-lIne therapy of preoperative cheMoradiothERApy with gemcitabine and nab-paclitaxel for locally advanced pancreatic canceR (SIMERAR trial)Patients with locally advanced pancreatic cancer (BR-A or UR-LA) scheduled for pancreatic resectionJPRN-UMIN000046618Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama45
Completed
Phase 2
Phase II trial of early secondary treatment with nibolumab for non-small cell lung cancernon-small cell lung cancerJPRN-UMIN000030457Fujita Health University School30
Active, not recruiting
Not Applicable
Phase II study of first line treatment of chronic graft versus host disease with the association of ciclosporine, corticosteroids and Rituximab - R-GVHDChronic graft versus host diseaseMedDRA version: 12.1Level: LLTClassification code 10066261Term: Chronic graft versus host diseaseEUCTR2009-016898-14-FRCHU de Nantes
Active, not recruiting
Phase 1
Phase II study of first line treatment of Chronic Graft versus Host Disease with Arsenic TrioxideFirst line treatment of Chronic Graft versus Host Disease in patients having received a first allogeneic stem cell transplantation for a hematological diseaseTherapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2016-002358-18-FRMedsenic24
Active, not recruiting
Phase 1
Ipilimumab, nivolumab and tocilizumab in pretreated patients with advanced pancreatic cancer.Pretreated patients with advanced pancreatic cancer.MedDRA version: 21.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033606Term: Pancreatic cancer non-resectableSystem Organ Class: 100000004864MedDRA version: 21.0Level: LLTClassification code 10033607Term: Pancreatic cancer recurrentSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-004438-40-DKDepartment of Oncology, Herlev & Gentofte Hospital30